New Drug Applications Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia 6 years ago
New Drug Applications US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis 6 years ago
New Drug Applications Xeris Pharmaceuticals Receives Notification of PDUFA Date Extension for Gvoke 6 years ago
New Drugs FDA Approves Keytruda (pembrolizumab) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma 6 years ago